Coegin Pharma's total inventories for the quarter that ended in Mar. 2026 was kr0.00 Mil. Coegin Pharma's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was kr0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Coegin Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was kr0.25.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Coegin Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 0.00.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Coegin Pharma's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.00.
Coegin Pharma (NGM:COEGIN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Coegin Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Coegin Pharma's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Coegin Pharma Total Inventories Related Terms
Coegin Pharma Total Inventories Historical Data
* Premium members only.
The historical data trend for Coegin Pharma's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Coegin Pharma (NGM:COEGIN) has a Total Inventories of kr0.00 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Coegin Pharma and its competitors.
Is Coegin Pharma's Total Inventories too high?
Coegin Pharma's current Total Inventories is kr0.00 Mil. Overall, Coegin Pharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Coegin Pharma's Total Inventories compare to VRTX and REGN?
Coegin Pharma's Total Inventories of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Coegin Pharma and its competitors. Coegin Pharma's current Total Inventories is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coegin Pharma stock overvalued right now?
Coegin Pharma (NGM:COEGIN) has a current Total Inventories of kr0.00 Mil. The current Total Inventories is kr0.00 Mil. Coegin Pharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Coegin Pharma (NGM:COEGIN), the current Total Inventories is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
29GF Score
Get the complete analysis for NGM:COEGIN
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:COEGIN has been successfully added to your 
